Jobs / United States / Abbvie INC
Senior Scientist I, Cell Line Development / Molecular Biology
Abbvie INC · 🇺🇸 San Francisco, CA, US
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 177 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 94 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Abbvie INC paid sponsored hires in similar roles2 certified filings for “Scientist I, Formulation and Process Development” (Chemists) in CA: $135k–$142k, median $139k. Most were filed at wage level III (50%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Abbvie INC
The US Department of Labor certified 177 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 94 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Abbvie INC →
About the role
The Biologics CMC Development organization at AbbVie has a long and rich history of biologics development, leveraging comprehensive end-to-end CMC capabilities to advance complex biologic therapies, such as bi-specifics and novel modalities, from discovery through human clinical studies and eventual licensure. The Cell Line Development (CLD) Innovation Group is seeking a Senior Scientist I to join a talented and collaborative team developing next-generation CHO cell line platforms for the production of recombinant antibodies and complex biologics. This is a hands-on, laboratory-focused role for a versatile molecular biologist who will independently drive expression-optimization projects across both the vector and the host cell — from experimental design through execution and data interpretation. The successful candidate will design and test vector constructs, engineer host cells, conduct transfection and clone-generation campaigns in CHO cells, and apply a deep theoretical understanding of recombinant protein expression to improve titer in stable cell lines. This is not a single-technique position: the role spans the full set of levers that govern expression, and the candidate is expected to think, read, and propose, then carry the work out at the bench with a high degree of independence. Responsibilities: • Independently conceive ideas and designs to investigate CHO expression technical improvements across both vector and host cell. • Design and test dozens of vector constructs in recombinant stable CHO cell lines for increased mAb titer. Rapidly execute the associated transfections, screening, and clone-characterization studies to generate decision-quality data. • Employ a variety of hands-on laboratory techniques, including transfection, aseptic CHO cell culture, DNA gene copy number analysis, RNA expression analysis (ddPCR / RT-qPCR), mAb titer measurement, cell engineering to knock in/out target genes. • Operate and interpret data from core CLD instrumentation, including Octet (BLI titer), ViCell, CloneSelect Imager, microfluidic clone-screening platforms such as the Beacon, flow cytometry. Share responsibility for equipment maintenance. • Apply a rigorous theoretical and practical understanding of recombinant protein expression from the genome to the protein — including genomic loci, epigenetics, transcription, mRNA stability, translation, the organelles and secretory machinery involved, and the engineering constraints specific to industrial CHO cell line development. • Author and co-author cell line development technical reports and present data to the group and to leadership; contribute scientific insight to project teams. • Collaborate closely with cell culture, analytical, purification, and bioinformatics colleagues to meet project timelines, and adhere to corporate standards for code of conduct, safety, materials handling, and good documentation practices. Required: • Senior Scientist I: BS with a minimum of 10 years, or MS with a minimum of 8 years of experience is strongly preferred , or PhD with no minimum years’ experience, in molecular biology, cell biology, biochemistry, or a related discipline. • Demonstrated ability to read the literature, review external sources, and gather inputs to synthesize technically sound ideas and design proper experimental controls. • Demonstrated ability to independently analyze experimental data, draw appropriate conclusions, and communicate them to a wide audience. • Demonstrated proficiency with designing and implementing vector improvements to increase recombinant antibody expression levels in stable CHO cells. • Proficiency with Geneious Prime or similar software for designing and annotating DNA vectors, primers, and probes, and performing sequence alignme